Susquehanna International Group, LLP Taysha Gene Therapies, Inc. Transaction History
Susquehanna International Group, LLP
- $823 Billion
- Q3 2025
A detailed history of Susquehanna International Group, LLP transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 21,742 shares of TSHA stock, worth $91,533. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,742
Previous 212,572
89.77%
Holding current value
$91,533
Previous $491,000
86.15%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding TSHA
# of Institutions
161Shares Held
247MCall Options Held
463KPut Options Held
246K-
Rtw Investments, LP New York, NY24.4MShares$103 Million1.03% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$99.2 Million1.27% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$91.4 Million0.93% of portfolio
-
Morgan Stanley New York, NY19.3MShares$81.3 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY13.4MShares$56.3 Million0.01% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $204M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...